New treatments for acute promyelocytic leukemia (APL) are needed. APL cell treatment with all-trans-retinoic acid (RA) degrades the chimeric, dominant negative-acting transcription factor PML/RARα, which is generated by chromosomal translocation. The E1-like ubiquitin-activating enzyme UBE1L associates with interferon stimulated gene ISG15 that This inhibitory effect promoted apoptosis but did not affect the differentiation response in these APL cells. In contrast, elevation of UBP43 expression stabilized PML/RARα protein and inhibited apoptosis. Taken together, our findings define UBP43 as a novel candidate drug target for APL treatment.
Gemini, Calabasas, CA), 4mM L-glutamine (Invitrogen), 100units/ml penicillin (Invitrogen), and 100µg/ml streptomycin (Invitrogen) (8, 9) . BEAS-2B immortalized human bronchial epithelial (HBE) cells were cultured in serum-free LHC-9 media (Biofluids, Akron, OH) (7, 8) .
COS-7 cells were cultured in Advanced DMEM (Invitrogen) media with 10% FBS, 4mM
L-glutamine, 100units/ml penicillin, and 100µg/ml streptomycin. Cells were incubated at 37 o C in a humidified incubator with 5% CO 2 .
Real-time RT-PCR Assays
Total cellular RNA was isolated using Trizol Reagent (Invitrogen) and cDNA synthesis was performed using the High-Capacity cDNA Transcription Kit (Applied Biosystems, Foster City, CA) and a Peltier Thermal Cycler (MJ Research, Waltham, MA). Real-time RT-PCR assays were performed with iTaq Fast SYBR Green Supermix with an ROX Kit (Bio-Rad, Hercules, CA) and the 7500 Fast Real-time PCR System (Applied Biosystems). Three independent replicate experiments were performed. Primers were: human UBP43 forward primer:
5'-GAGGCTGGACGCTTGCAT-3' and reverse primer:
5'-AGCACGACTTCACTTCCAGGAA-3'; human UBE1L forward primer:
5'-TGGGCACCTTGTGTCATAAGC-3' and reverse primer:
5'-CTCAGAGTGAGAATGCCAGGG-3'; human ISG15 forward primer:
5'-TGTCGGTGTCAGAGCTGAAG-3' and reverse primer:
5'-GCCCTTGTTATTCCTCACCA-3'; human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primer: 5'-ACGTGTCAGTCAGTGGTGGACCT-3' and reverse primer:
5'-GTCCACCACCCTGTTGCTG-3'. The following primers detected murine species:
UBP43 forward primer: 5'-TTGGGCTCCTGAGGAAACC-3', and reverse primer:
5'-CGATGTTGTGTAAACCAACCAGA-3'; UBE1L forward primer:
5'-CTACGAGCGACTCCATATACCT-3' and reverse primer:
5'-TACACACAGGGTAGGGAGCAT-3'; ISG15 forward primer:
5'-AACTGCAGCGAGCCTCTGA-3' and reverse primer:
5'-CACCTTCTTCTTAAGCGTGTCTACAG-3'; GAPDH forward primer:
5'-AGGTCGGTGTGAACGGATTTG-3' and reverse primer:
5'-TGTAGACCATGTAGTTGAGGTCA-3'.
Expression Plasmids and Transient Transfection
The pcDNA4-UBP43, pSG5-UBE1L, His 6 -tagged-pcDNA3-ISG15, pCMV-hemagglutinin (HA)-PML/RARα, pCMV-HA-PML, and pCMV-HA-RARα expression vectors were previously described (7) (8) (9) . The full-length coding region of human UBP43 was cloned into the pRetroX-IRES-ZsGreen1 vector (Clontech, Mountain View, CA) at BamH1 and Not1 restriction endonuclease sites to engineer the pRetroX-IRES-ZsGreen1-UBP43 retrovirus.
The insertless retrovirus served as a control. The enhanced green fluorescent protein (EGFP) expression plasmid (EGFP-N2, Clontech), shRNA-UBP43 retroviruses (Open (5'-GGAAGAAGACAGCAACATG-3'). Transfection efficiency was monitored by co-transfecting the siGLO Green Transfection Indicator (Dharmacon).
Generation of Stable UBP43 Expressing APL Transfectants
The pRetroX-IRES-ZsGreen1-UBP43 retroviral vector and an insertless control retrovirus were independently transfected into the RetroPack PT67 Packaging Cell Line (Clontech) using FuGENE 6 (Roche, Indianapolis, IN). Viral supernatants from transfectants were used to transduce NB4-R1 or NB4-S1 cells with 4μg/ml polybrene (Sigma, Milwaukee, WI). GFP positive cells were harvested 48 hours later using a FACStar Plus cytometer (Becton Dickinson, San Jose, CA). This was repeated a week later to enrich for transductants, as before (7) . Doubly selected cells were studied. Three independent
Research. RA-treated and control mice were independently sacrificed at indicated time points using IACUC-approved procedures. APL cells were harvested from spleens, as in prior work (32) .
Total RNA was isolated as before (7-9) for real-time RT-PCR assays. Findings from all mice treated in each respective arm were pooled for analyses.
UBP43 Expression in Human APL Cells
Fresh APL cells were harvested as part of an Institutional Review Board (IRB) approved protocol using previously optimized methods (32 hours of RA-treatment and results were compared to vehicle controls.
Statistical Analyses
Two-tailed T-tests were used. Results appear as means ± standard deviation (SD).
Research. Statistical significance is noted in the text and figures as well as with these symbols: P < 0.01 (*) and P < 0.005 (**).
Results

UBP43 Expression in APL Cells
UBE1L, a retinoid target (7, 8) , along with its ubiquitin-like partner ISG15, destabilized PML/RARα (9) and cyclin D1 (33) via ISG15 conjugation to these respective proteins. That the ISG15 deconjugase UBP43 antagonized UBE1L-mediated repression of these proteins (9,33) implicated UBP43 as a pharmacologic target. This study determined RA-treatment effects on mRNA expression profiles of UBE1L, ISG15, and UBP43 in RA-sensitive NB4-S1
and in RA-resistant NB4-R1 APL cells using real-time RT-PCR assays (Fig. 1A ). UBE1L
and ISG15 mRNA expression profiles were augmented by RA-treatment beginning at 12
hours and these increased further in NB4-S1 cells at later time points (Fig. 1A) . The maximal induction observed after RA-treatment was at 72 hours for UBE1L, at 96 hours for ISG15, and at 48 hours for UBP43.
In contrast, UBE1L, ISG15 and UBP43 inductions were markedly blunted despite RA-treatment of NB4-R1 APL cells. UBP43 mRNA expression (relative to vehicle controls) was augmented by RA-treatment of NB4-S1 cells after observed increases in UBE1L and 
UBP43 Protein Expression in APL Cells
Different rabbit polyclonal antibodies recognizing UBP43 protein were derived (see UBP43 is reported as the protease specific for ISG15 (13, 34) . To confirm that the PML/RARα protein (8, 9) . UBP43 mRNA induction followed that of UBE1L and ISG15 mRNAs, raising the possibility that UBP43 directly affected PML/RARα protein stability.
Experiments were conducted to examine this. To study further UBP43 effects on PML-RARα protein stability, UBP43 was co-transfected with an HA-tagged PML-RARα expression vector in BEAS-2B cells in the presence and absence of the protein synthesis inhibitor CHX. UBP43 transfection increased PML-RARα protein stability, despite CHX treatment (Fig.3B ).
UBP43
UBP43 and Apoptosis
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Copyright © 2010 American Association for Cancer Research 14 Prior work found that UBE1L triggered PML/RARα degradation and apoptosis in APL cells (7) (8) (9) . Whether UBP43 affected apoptosis in APL cells by targeting PML-RARα protein was studied. To ascertain effects of UBP43 on PML/RARα expression, two different siRNAs targeting UBP43 and a RISC-free control siRNA were independently transfected into NB4-S1 cells (Fig. 3C, left panel) . Knock-down of UBP43 by each of these UBP43-targeting siRNAs significantly decreased UBP43 and PML/RARα immunoblot expression versus controls in APL cells. Actin expression was unaffected (Fig. 3C) . Compared with RISC-free siRNA controls, knock-down of UBP43 by each siRNA targeting UBP43 significantly augmented apoptosis, as confirmed by annexin V and propidium iodide (PI) staining and fluorescence activated cell sorting (FACS) analysis (Fig. 3D ). Compared to RISC-free control cells, UBP43 knock-down in NB4-S1 cells augmented apoptosis at day 1 and this increased over the 3 days of this study. A decline in PML/RARα protein accompanied this (Fig. 3C ).
To confirm and extend these transient UBP43 knock-down findings, stable retroviral shRNA-mediated repression of UBP43 was achieved. The consequences of this on PML/RARα expression and on apoptosis were studied in NB4 transductants. Stable knock-down of UBP43 was engineered by retroviral transductions and puromycin selection of the desired shRNA independently expressed in NB4-R1 and NB4-S1 cells. Fig. 4A established that shRNA-mediated UBP43 knock-down reduced endogenous PML/RARα expression in both transduced APL cell lines (relative to insertless vector controls). Stable UBP43 knock-down in NB4-R1 and NB4-S1 cells significantly increased apoptosis in both cells (Fig. 4B) . RA-treatment of UBP43 knock-down NB4-S1 cells did significantly promote
Copyright © 2010 American Association for Cancer Research 15 apoptosis, but did not affect differentiation response (supplemental Fig. 1 ). Fig. 4B showed that compared with these respective control transfectants, UBP43 knock-down in these APL cells produced significant (**, P < 0.005) apoptosis.
UBP43 over-expression was independently achieved in NB4-S1 and NB4-R1 cells, as shown in Fig. 5 . Unlike UBP43 knock-down, retroviral-mediated UBP43 over-expression augmented PML/RARα expression in both APL cell lines (Fig. 5A ) and reduced apoptosis (Fig. 5B) relative to insertless vector controls.
UBP43 Regulated APL Cell Growth
Since UBP43 knock-down promoted apoptosis in APL cells by targeting PML/RARα for repression, effects of UBP43 knock-down on growth were studied in NB4 cells with engineered loss or gain of UBP43 expression. CellTiter-Glo assays confirmed that UBP43
knock-down conferred a marked repression of NB4-S1 and NB4-R1 cell growth (Fig. 4C) . In contrast, engineered UBP43 over-expression significantly (**, P < 0.005) promoted growth, as compared to insertless vector controls for both APL cell lines (Fig. 5C ).
RA-Treatment of APL Mice
To determine whether RA induced UBP43 expression in vivo, a murine transgenic transplantable APL model was studied (35) . Clinical evidence of APL occurred in recipients 20 days after transgenic APL cell injections into FVB mice. Mice were then sacrificed and RNA was isolated from harvested spleens (see Materials and Methods). UBE1L, ISG15 and UBP43 mRNA expression profiles were each significantly augmented after RA-treatment versus vehicle control-treated APL mice (Fig. 6A ). These findings extended results from cultured APL cells to the setting of APL in mice.
RA-Treatment of APL Cells from Patients
Whether RA increased UBE1L, ISG15 and UBP43 mRNA expression profiles in cultures of leukemic cells was studied in APL cells harvested directly from patients. APL cells from two different RA-responsive cases augmented UBE1L, ISG15 and UBP43 mRNA expression after 24 hours of RA-treatment relative to controls (Fig. 6B) . No significant change in UBE1L expression was observed, but when the ISG15 and UBP43 results after RA-treatment were pooled, significant changes were observed (P = 0.0024, N = 3).
RA-treatment also caused differentiation to occur in RA-sensitive cases, as shown by increased NBT positive APL cells (Fig. 6B ). Cells from a representative RA-resistant APL case with an inactivating PML/RARα ligand-binding domain mutation similar to that in NB4-R1 cells (36, 37) were examined. Deregulated UBE1L, ISG15 and UBP43 expression and minimal NBT augmentation were observed, despite RA-treatment of these APL cells (Fig. 6B) .
Discussion
This study builds on prior work that revealed retinoid treatment of APL cells augmented UBE1L and ISG15 expression and ISG15ylation (8, 9) by showing that the deconjugase, UBP43, is also regulated by RA-treatment of APL cells. RA-induction of UBP43 mRNA did not increase until 48 hours (Fig. 1A) . That retinoid effects on UBP43 were indirect was consistent with bioinformatic analysis and UBP43 reporter assay results. RA-mediated induction of UBP43 occurred in RA-sensitive, but not in RA-resistant APL cells (Figs. 1 and   2 ). RA-treatment also augmented UBE1L and ISG15 mRNA expression in RA-sensitive, but not in RA-resistant APL cells. Increased UBE1L and ISG15 expression accompanied 
UBP43 protein was detected in COS-7 cells transfected with pcDNA4-UBP43 (+), but not
with an insertless control pcDNA4 vector (-). The 43-kDa UBP43 protein was detected using these respective antibodies. This protein was not detected when pre-immune antisera for each antibody was probed to each respective filter. Molecular weight size markers are displayed. 
